JP2012526131A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526131A5 JP2012526131A5 JP2012509947A JP2012509947A JP2012526131A5 JP 2012526131 A5 JP2012526131 A5 JP 2012526131A5 JP 2012509947 A JP2012509947 A JP 2012509947A JP 2012509947 A JP2012509947 A JP 2012509947A JP 2012526131 A5 JP2012526131 A5 JP 2012526131A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- halogen
- optionally
- compound according
- aliphatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 77
- 229910052736 halogen Inorganic materials 0.000 claims description 58
- 150000002367 halogens Chemical class 0.000 claims description 53
- 125000001931 aliphatic group Chemical group 0.000 claims description 48
- 229910052799 carbon Inorganic materials 0.000 claims description 42
- 229920006395 saturated elastomer Polymers 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 22
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 230000001404 mediated effect Effects 0.000 claims description 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 18
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 125000002950 monocyclic group Chemical group 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 208000023275 Autoimmune disease Diseases 0.000 claims description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 10
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 8
- 125000002252 acyl group Chemical group 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000002837 carbocyclic group Chemical group 0.000 claims description 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 102000001253 Protein Kinase Human genes 0.000 claims description 5
- 108060006633 protein kinase Proteins 0.000 claims description 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 4
- 102000003923 Protein Kinase C Human genes 0.000 claims description 4
- 208000000389 T-cell leukemia Diseases 0.000 claims description 4
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 4
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000003725 azepanyl group Chemical group 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000005959 diazepanyl group Chemical group 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 125000001984 thiazolidinyl group Chemical group 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 230000003463 hyperproliferative effect Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 208000018937 joint inflammation Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- -1 or a -T1-Q1 Chemical class 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17589709P | 2009-05-06 | 2009-05-06 | |
| US61/175,897 | 2009-05-06 | ||
| PCT/US2010/033720 WO2010129668A1 (en) | 2009-05-06 | 2010-05-05 | Pyrazolopyridines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012526131A JP2012526131A (ja) | 2012-10-25 |
| JP2012526131A5 true JP2012526131A5 (https=) | 2013-06-27 |
| JP5627675B2 JP5627675B2 (ja) | 2014-11-19 |
Family
ID=42358193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012509947A Expired - Fee Related JP5627675B2 (ja) | 2009-05-06 | 2010-05-05 | ピラゾロピリジン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8541445B2 (https=) |
| EP (1) | EP2427464A1 (https=) |
| JP (1) | JP5627675B2 (https=) |
| CN (1) | CN102459259A (https=) |
| AU (1) | AU2010245914A1 (https=) |
| CA (1) | CA2760705A1 (https=) |
| MX (1) | MX2011011653A (https=) |
| WO (1) | WO2010129668A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8569337B2 (en) | 2008-07-23 | 2013-10-29 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| MX2011001319A (es) * | 2008-08-06 | 2011-04-05 | Vertex Pharma | Inhibidores de aminopiridina cinasa. |
| RS57869B1 (sr) | 2009-06-17 | 2018-12-31 | Vertex Pharma | Inhibitori replikacije virusa gripa |
| US9266880B2 (en) | 2010-11-12 | 2016-02-23 | Bristol-Myers Squibb Company | Substituted azaindazole compounds |
| AU2011343642A1 (en) | 2010-12-16 | 2013-05-02 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| US8846712B2 (en) | 2011-09-12 | 2014-09-30 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (en) * | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013037390A1 (en) * | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8969586B2 (en) | 2011-09-27 | 2015-03-03 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
| EP2760862B1 (en) * | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2771340B1 (en) * | 2011-10-25 | 2016-04-13 | Sanofi | 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2847191B1 (en) | 2012-05-09 | 2016-06-15 | Sanofi | Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors |
| HRP20181272T1 (hr) | 2013-11-13 | 2018-10-05 | Vertex Pharmaceuticals Incorporated | Postupci priprave inhibitora replikacije virusa influence |
| RS59144B1 (sr) | 2013-11-13 | 2019-09-30 | Vertex Pharma | Inhibitori replikacije virusa influence |
| JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| JP6857617B2 (ja) | 2015-05-13 | 2021-04-14 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤 |
| CN110483440A (zh) * | 2018-06-11 | 2019-11-22 | 上海睿升化工科技有限公司 | 一种2-(2-溴-1,3-噻唑-5-基)乙腈的制备方法 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3853898A (en) | 1971-07-20 | 1974-12-10 | Sandoz Ag | 3-(2-substituted amino) pyridyl-phenyl ketone imines |
| US4988705A (en) | 1985-06-13 | 1991-01-29 | Schering Corporation | Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives |
| FR2601015B1 (fr) | 1986-07-04 | 1988-08-05 | Rhone Poulenc Sante | Nouveaux derives du 1h,3h-pyrrolo (1,2-c) thiazole, leur preparation et les compositions pharmaceutiques qui les contiennent |
| DE3827253A1 (de) | 1987-08-20 | 1989-03-02 | Sandoz Ag | Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen |
| CA1339423C (en) | 1988-09-14 | 1997-09-02 | Yuji Ono | Pyridine compounds and pharmaceutical use thereof |
| US5100768A (en) | 1989-05-09 | 1992-03-31 | Kabushiki Kaisha Toshiba | Photosensitive composition |
| JPH03206450A (ja) | 1990-01-09 | 1991-09-09 | Fuji Photo Film Co Ltd | 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料及びその処理方法 |
| US5308854A (en) | 1990-06-18 | 1994-05-03 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
| JPH05331163A (ja) | 1991-03-26 | 1993-12-14 | Kumiai Chem Ind Co Ltd | ピリジン誘導体及び除草剤 |
| UA44220C2 (uk) | 1991-11-07 | 2002-02-15 | Агрево Юк Лімітед | Сульфонаміди,що мають гербіцидну активність,спосіб їх одержання, гербіцидна композиція та спосіб боротьби з бур'янами |
| US5476750A (en) | 1992-12-29 | 1995-12-19 | Hoechst Celanese Corporation | Metal ion reduction in the raw materials and using a Lewis base to control molecular weight of novolak resin to be used in positive photoresists |
| DE69404306T2 (de) | 1993-05-28 | 1997-10-30 | Pfizer | Verfahren zur herstellung und optischen auflösung von 2-phenyl-3-aminopiperidine |
| CA2133355A1 (en) | 1993-10-04 | 1995-04-05 | Itaru Nitta | Method for producing polypeptide |
| WO1995032963A1 (en) | 1994-06-01 | 1995-12-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienylazole compound and thienotriazolodiazepine compound |
| KR970705562A (ko) | 1994-08-29 | 1997-10-09 | 오노다 마사요시 | 신규한 나프티리딘 유도체 및 이의 의약 조성물(Novel naphthyridine derivatives and medicinal composition thereof) |
| US5646330A (en) | 1995-02-17 | 1997-07-08 | Ciba-Geigy Corporation | Production of enantiomerically enriched ortho-substituted α,α-diaromatic methanols |
| US6194581B1 (en) | 1995-04-07 | 2001-02-27 | Merck & Co., Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| NZ322197A (en) | 1995-11-21 | 1999-02-25 | Yamanouchi Pharma Co Ltd | Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof |
| AU6748398A (en) | 1997-04-18 | 1998-11-13 | Kissei Pharmaceutical Co. Ltd. | Preventives or remedies for diseases affecting excessive proliferation of retinal pigment epithelial cells |
| AU8033598A (en) | 1997-06-18 | 1999-01-04 | Nissan Chemical Industries Ltd. | Pyridine compounds and herbicides |
| US6452008B2 (en) | 1998-02-25 | 2002-09-17 | Sumitomo Pharmaceuticals Company, Limited | Pyridone derivatives and process for preparing the same |
| US6225329B1 (en) | 1998-03-12 | 2001-05-01 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPases) |
| GB9908410D0 (en) | 1999-04-13 | 1999-06-09 | Pfizer Ltd | Pyridines |
| US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| US20020115642A1 (en) | 2000-05-02 | 2002-08-22 | Chan Ming Fai | Beta-lactam antibiotics |
| AR029289A1 (es) | 2000-07-05 | 2003-06-18 | Ishihara Sangyo Kaisha | Derivado de benzoilpiridina o su sal, fungicida que lo contiene como un ingrediente activo, su proceso de produccion e intermediario para producirlo |
| DE10035908A1 (de) | 2000-07-21 | 2002-03-07 | Asta Medica Ag | Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel |
| PL362546A1 (en) | 2000-10-05 | 2004-11-02 | Fujisawa Pharmaceutical Co, Ltd. | Benzamide compounds as apo b secretion inhibitors |
| ES2200617B1 (es) | 2001-01-19 | 2005-05-01 | Almirall Prodesfarma, S.A. | Derivados de urea como antagonistas de integrinas alfa 4. |
| GB2373245A (en) | 2001-03-12 | 2002-09-18 | Bayer Ag | Pyridinyl pyrazoles and their use for the treatment of COPD |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| MXPA04004178A (es) | 2001-11-01 | 2004-09-06 | Janssen Pharmaceutica Nv | Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta. |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| EP2399903A1 (en) | 2002-05-24 | 2011-12-28 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
| EP1545515A1 (en) | 2002-08-12 | 2005-06-29 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| AP2005003365A0 (en) | 2003-02-07 | 2005-09-30 | Janssen Pharmaceutica Nv | Hiv inhibiting 1, 2, 4-triazines. |
| ES2305735T3 (es) | 2003-02-28 | 2008-11-01 | Schering Corporation | Biariltetrahidroisoquinolin-piperidinas como antagonistas del receptor de mch selectivos, para el tratamiento de obesidad y trastornos relacionados. |
| US20050203067A1 (en) | 2003-05-12 | 2005-09-15 | Hresko Michelle C. | Pesticidal compositions and methods |
| WO2005000813A1 (en) | 2003-05-30 | 2005-01-06 | Imclone Systems Incorporated | Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors |
| AU2004259755A1 (en) | 2003-07-22 | 2005-02-03 | Janssen Pharmaceutica, N.V. | Quinolinone derivatives as inhibitors of c-fms kinase |
| DE602004031641D1 (de) | 2003-09-25 | 2011-04-14 | Janssen Pharmaceutica Nv | Die replikation von hiv hemmende purinderivate |
| EP1689722A2 (en) | 2003-10-10 | 2006-08-16 | Bayer Pharmaceuticals Corporation | 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders |
| CA2545821C (en) | 2003-12-22 | 2010-09-21 | Basilea Pharmaceutica Ag | Aroylfuranes and aroylthiophenes |
| KR20070002081A (ko) | 2004-04-02 | 2007-01-04 | 버텍스 파마슈티칼스 인코포레이티드 | Ｒｏｃｋ 및 기타 단백질 키나아제의 억제제로서 유용한아자인돌 |
| US20070275954A1 (en) | 2004-05-19 | 2007-11-29 | Astrazeneca Ab | Novel Fused Heterocycles and Uses Thereof |
| EP1781654A1 (en) | 2004-07-27 | 2007-05-09 | SGX Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| US7361764B2 (en) | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| US7709645B2 (en) | 2004-07-27 | 2010-05-04 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| US20090227799A1 (en) | 2004-08-09 | 2009-09-10 | Kazutaka Nakamoto | Novel Antimalarial Agent Containing Heterocyclic Compound |
| US7812166B2 (en) * | 2004-10-29 | 2010-10-12 | Abbott Laboratories | Kinase inhibitors |
| DE602006014502D1 (de) | 2005-01-14 | 2010-07-08 | Janssen Pharmaceutica Nv | Pyrazolopyrimidine als zellzyklus-kinasehemmer |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| DE602006012815D1 (de) | 2005-03-23 | 2010-04-22 | Hoffmann La Roche | Acetylenylpyrazolopyrimidinderivate als mglur2-antagonsten |
| US20060270709A1 (en) | 2005-04-04 | 2006-11-30 | Eisai Co. Ltd. | Dihydropyridine compounds and compositions for headaches |
| AU2006234627C1 (en) | 2005-04-08 | 2009-11-26 | Eisai R & D Management Co., Ltd. | Therapeutic agent for dyskinesia |
| DE602006014540D1 (en) * | 2005-05-16 | 2010-07-08 | Irm Llc | Pyrrolopyridinderivate als proteinkinaseinhibitoren |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
| AU2008210455A1 (en) | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as kinase inhibitors |
| CA2704266A1 (en) * | 2007-11-02 | 2009-06-11 | Vertex Pharmaceuticals Incorporated | [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta |
-
2010
- 2010-05-05 CA CA2760705A patent/CA2760705A1/en not_active Abandoned
- 2010-05-05 WO PCT/US2010/033720 patent/WO2010129668A1/en not_active Ceased
- 2010-05-05 JP JP2012509947A patent/JP5627675B2/ja not_active Expired - Fee Related
- 2010-05-05 EP EP10731839A patent/EP2427464A1/en not_active Withdrawn
- 2010-05-05 CN CN2010800265229A patent/CN102459259A/zh active Pending
- 2010-05-05 AU AU2010245914A patent/AU2010245914A1/en not_active Abandoned
- 2010-05-05 MX MX2011011653A patent/MX2011011653A/es unknown
-
2011
- 2011-11-04 US US13/289,320 patent/US8541445B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526131A5 (https=) | ||
| JP2011502994A5 (https=) | ||
| JP2013530236A5 (https=) | ||
| JP5535204B2 (ja) | 抗ウイルス特性を有する化合物 | |
| JP2013533883A5 (https=) | ||
| JP2014524934A5 (https=) | ||
| AR069174A1 (es) | Derivados de pirazolo[3,4-b]-piridina inhibidores de proteinquinasas, procesos de preparacion, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias o proliferativas. | |
| JP2013533884A5 (https=) | ||
| JP2016536363A5 (https=) | ||
| JP2019532079A5 (https=) | ||
| JP2016536364A5 (https=) | ||
| AR044762A1 (es) | Derivados de ester y amida del acido 2-cianopropanoico, un proceso para su preparacion y el uso de dichos derivados para la preparacion de un medicamento | |
| JP2014510147A5 (https=) | ||
| JP2014506599A5 (https=) | ||
| JP2016531113A5 (https=) | ||
| RU2015115400A (ru) | Гетероароматические соединения и их применение в качестве допаминовых D1 лигантов | |
| JP2014504632A5 (https=) | ||
| EA201400163A1 (ru) | Замещенные хинолины и их применение в качестве лекарственных средств | |
| JP2012511588A5 (https=) | ||
| JP2017503760A5 (https=) | ||
| AU2017246455A1 (en) | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | |
| JP2020500916A5 (https=) | ||
| JP2017525699A5 (https=) | ||
| JP2015500842A5 (https=) | ||
| JP2019501927A5 (https=) |